Lakefront Biotherapeutics (LKFT) Non-Current Deffered Revenue (2016 - 2025)

Lakefront Biotherapeutics (LKFT) has 10 years of Non-Current Deffered Revenue data on file, last reported at $779.0 million in Q3 2025.

• Non-Current Deffered Revenue for Q3 2025 came in at $779.0 million, down 20.93% year-over-year; the trailing twelve-month figure through Sep 2025 was $779.0 million (down 20.93% YoY), and the FY2024 annual result was $896.4 million, down 22.22% from the prior year.
• Non-Current Deffered Revenue declined to $779.0 million in Q3 2025 per LKFT's latest filing, from $819.3 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $2.6 billion in Q2 2021 and troughed at $779.0 million in Q3 2025.
• A 5-year average of $1.4 billion and a median of $1.2 billion in 2023 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2021 and 2024: Non-Current Deffered Revenue declined 3.0% in 2021, then tumbled 31.35% in 2024.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $2.2 billion in 2021, then dropped by 25.55% to $1.7 billion in 2022, then plunged by 30.42% to $1.2 billion in 2023, then decreased by 22.22% to $896.4 million in 2024, then decreased by 13.1% to $779.0 million in 2025.
• Business Quant data shows LKFT's Non-Current Deffered Revenue at $779.0 million in Q3 2025, $819.3 million in Q2 2025, and $821.9 million in Q1 2025.